DM

1109 Words3 Pages

Diabetes mellitus is a collection of metabolic disorders of protein, carbohydrate, and fat metabolism that results in defects in insulin sensitivity and/or insulin secretion. The incidence of T2DM is increasing and has been attributed to increasing obesity, the Western-style diet, an increasing minority population, and a sedentary lifestyle.1 Type 2 is a combined insulin resistance and relative deficiency in insulin secretion. It is associated with both macrovascular and microvascular complications. Diagnosis is contingent on four criteria: FPG >126 mg/dL, a 2-hour OGTT of >200 mg/dL, a casual plasma glucose level of >200 mg/dL with symptoms of diabetes, or a HbA1c >6.5%.1 The diagnosis should be repeated to confirm if obvious hyperglycemia is not present. Goals of therapy are to attain normoglycemia, reduce the progression/onset of retinopathy, neuropathy, and nephropathy complications, and improve the quantity and quality of life. Metformin should be included in therapy, as it is the only oral antihyperglycemic medication that will reduce the risk of total mortality.1 Type 2 treatment usually requires the use of combination drug therapy, including oral and/or injected agents and insulin to achieve glycemic goals due to the persistent loss in pancreatic beta cell function over time. Cardiovascular disease risk factors must be managed aggressively to reduce the risk for death or adverse cardiovascular events. Antiplatelet therapy is needed as a secondary prevention strategy. Also need aggressive management of dyslipidemia and treatment of hypertension. A cornerstone of type 2 diabetes treatment is lifestyle modification, dietary restriction of fat, weight loss, and aerobic exercise for 30 minutes 5 times per week.1 To have a succe...

... middle of paper ...

...proved and thus, an A1c target of <6% is not recommended. These trials found that although it is possible to achieve aggressive glycemic control, the number of deaths from hypoglycemic events does not warrant this intensive control.4 Standard control (A1c <8%) was the resulting recommendation made, except for some low risk patient populations. The ADVANCE trial showed that A1c targets <6.5% improved microvascular outcomes such as retinopathy, neuropathy, and nephropathy, but had no impact on macrovascular outcomes like stroke and myocardial infarction. Together, these trials suggest that intensive glycemic therapy alone is not going to give the diabetic patients a cardiovascular benefit. The only patient populations that are likely to receive benefit from intensive glycemic control are newly diagnosed diabetics without a significant risk of coronary artery disease.4

Open Document